See why the Regenlab patented system is not just another tube

Closed-System PRP Preparation: Improving Safety and Standardisation in Clinic

In daily practice, not all tubes are equivalent when it comes to preparing PRP (Platelet-Rich Plasma). Beyond appearance, the key differences come down to regulatory compliance and patient safety.

3

1) In Europe, PRP preparation requires a compliant medical device

To be legally placed on the market and used for PRP preparation in the EU, dedicated devices should carry a CE mark.
Importantly, where applicable, this CE mark is accompanied by the number of the Notified Body—a practical way to distinguish a compliant medical device from a standard laboratory consumable.

2) “Laboratory/IVD” tubes vs PRP medical devices: a safety gap

Tubes labelled “For laboratory use only” are not intended for clinical PRP preparation. Using a non-certified tube for this purpose may compromise patient safety and increase the risk of adverse events.

3) The patented RegenLab system: a closed circuit designed for standardisation

RegenLab PRP devices are engineered as a closed-circuit system, with a clear objective:

  • minimise handling

  • reduce contamination risk

  • support a more standardised, repeatable preparation process in clinic

4) Optimised separation after centrifugation

Following centrifugation (as shown in the video: 1500 × g), the separator gel helps isolate plasma and platelets from red and white blood cells. This design supports a cleaner, usable plasma fraction for the next steps of the protocol.

5) A simple step that matters: homogenisation

The final step highlighted is gentle mixing: tilt/rock the tube at least 20 times to re-suspend platelets into the plasma and obtain a homogeneous PRP (RegenPRP™).

|

The ORIGINAL and the SAFE Choice for PRP Preparation

|

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.